TY - JOUR
T1 - Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats
AU - Karau, Melissa J.
AU - Schmidt-Malan, Suzannah M.
AU - Yan, Qun
AU - Greenwood-Quaintance, Kerryl E.
AU - Mandrekar, Jayawant
AU - Lehoux, Dario
AU - Schuch, Raymond
AU - Cassino, Cara
AU - Patel, Robin
N1 - Publisher Copyright:
Copyright © 2019 American Society for Microbiology. All Rights Reserved.
PY - 2019
Y1 - 2019
N2 - Bacteriophage-derived lysins are being developed as anti-infective agents. In an acute osteomyelitis methicillin-resistant Staphylococcus aureus (MRSA) model, rats receiving no treatment or treatment with daptomycin, exebacase (CF-301), or daptomycin plus exebacase had means of 5.13, 4.09, 4.65, and 3.57 log10 CFU/gram of bone, respectively. All treated animals had fewer bacteria than did untreated animals (P≤ 0.0001), with daptomycin plus exebacase being more active than daptomycin (P= 0.0042) or exebacase (P < 0.001) alone.
AB - Bacteriophage-derived lysins are being developed as anti-infective agents. In an acute osteomyelitis methicillin-resistant Staphylococcus aureus (MRSA) model, rats receiving no treatment or treatment with daptomycin, exebacase (CF-301), or daptomycin plus exebacase had means of 5.13, 4.09, 4.65, and 3.57 log10 CFU/gram of bone, respectively. All treated animals had fewer bacteria than did untreated animals (P≤ 0.0001), with daptomycin plus exebacase being more active than daptomycin (P= 0.0042) or exebacase (P < 0.001) alone.
KW - CF-301
KW - Daptomycin
KW - Exebacase
KW - Methicillin-resistant Staphylococcus aureus
KW - Osteomyelitis
UR - http://www.scopus.com/inward/record.url?scp=85072563069&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072563069&partnerID=8YFLogxK
U2 - 10.1128/AAC.01122-19
DO - 10.1128/AAC.01122-19
M3 - Article
C2 - 31358593
AN - SCOPUS:85072563069
SN - 0066-4804
VL - 63
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 10
M1 - e01235-19
ER -